AMIX AUTONOMIX MEDICAL INC

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit

THE WOODLANDS, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the on Tuesday, March 18, 2025 at 7:35 AM PT.

In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

The in-person presentation will be accessible to those registered to attend the event. For more information, please visit the .

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit and connect with the Company on , , and .

Investor and Media Contact

JTC Team, LLC

Jenene Thomas

908.824.0775



EN
26/02/2025

Underlying

AMIXAUTONOMIX MEDICAL INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AUTONOMIX MEDICAL INC

 PRESS RELEASE
Free
AMIX AUTONOMIX MEDIC...

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Hu...

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain  Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix’s strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or ...

June 5, 2025 1 EN
 PRESS RELEASE
Free
AMIX AUTONOMIX MEDIC...

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Cathete...

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology Patent strengthens Autonomix’s intellectual property position in the nerve-mapping and denervation space, supporting the Company’s broader mission to advance minimally invasive, nerve-focused therapeutics Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, May 15, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerv...

May 15, 2025 1 EN
 PRESS RELEASE
Free
AMIX AUTONOMIX MEDIC...

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bel...

Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event Live webcast followed by an interactive Q&A session on Thursday, May 22nd at 4:00 PM ET Access the event THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the on Thursday, May 22, 2025 at 4:00 PM ET. As part of the event, of Autonomix, will provide a corporate overview and discuss the Company’s first-in-class platform system technology,...

May 14, 2025 1 EN
 PRESS RELEASE
Free
AMIX AUTONOMIX MEDIC...

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansi...

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Additional indications potentially double the addressable market beyond pancreatic cancer pain Follow-on expansion phase expected to begin in Q2 2025 THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) -- –  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advan...

May 13, 2025 1 EN
 PRESS RELEASE
Free
AMIX AUTONOMIX MEDIC...

Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain...

Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care THE WOODLANDS, TX, May 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the release of...

May 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch